EN DE

PT Phapros Tbk, (PEHA) Fair Value & Analysis

Healthcare · ID · Market cap 215B IDR

PP PT Phapros Tbk, PEHA · JK
Price266.00 IDR
Fair Value734.16 IDR
Upside+176.0%
Quality66/100
Watch PT Phapros Tbk, for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 3.7% net margin
Moderate debt · generates free cash flow
1.94% dividend yield
Ranks above peers (11/14)
Narrow moat 38/100
Evidence: High Range 415.54 IDR – 917.69 IDR Share as image

Fair value as of: Jul 19, 2026

From 25 valuation models · updated 22 days ago

Share price +5.6% over the past month.

A solid business, screening 176% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (415.54 IDR). The market is more pessimistic than our downside scenario.
  • Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (415.54 IDR to 917.69 IDR) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

1,350 IDR 209.97 IDR Fair Value 734.16 IDR Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range 209.97 IDR – 1,350 IDR · fair‑value band 415.54 IDR – 917.69 IDR · the 266.00 IDR price screens below the 734.16 IDR fair value. Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PT Phapros Tbk, (PEHA) currently trades at 266.00 IDR, while our model-based Fair Value estimate is 734.16 IDR, implying the stock looks roughly 176.0% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, PT Phapros Tbk, generated revenue of 961B IDR at a net margin of 3.7%. Revenue grew 10.2% year over year. It earns a return on equity of 8.4%. Net debt stands at 586B IDR. Fundamentals as of Jul 19, 2026

Our scenario range runs from 415.54 IDR (bear case) to 917.69 IDR (bull case); at 266.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 29% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 176%, PEHA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 365.45 IDR 770.85 IDR 1,359 IDR 80
Residual Income 401.20 IDR 420.89 IDR 454.84 IDR 76
Rev-Margin DCF 341.90 IDR 835.57 IDR 1,371 IDR 74
All 25 models by family
DCF Models
FCF DCF 337.84 IDR 774.12 IDR 1,436 IDR 38
Owner Earnings 424.27 IDR 903.47 IDR 1,630 IDR 31
5Y Revenue Exit 341.90 IDR 829.41 IDR 1,434 IDR 39
5Y EBITDA Exit 740.61 IDR 1,545 IDR 2,454 IDR 41
5Y P/E Exit 79.90 IDR 359.23 IDR 636.63 IDR 38
10Y Revenue Exit 304.05 IDR 748.14 IDR 1,307 IDR 36
10Y EBITDA Exit 588.35 IDR 1,245 IDR 2,074 IDR 37
10Y P/E Exit 164.51 IDR 421.45 IDR 707.53 IDR 35
Earnings-Based
Graham-Dodd 226.92 IDR 561.87 IDR 728.14 IDR 54
PEG = 1.0 101.85 IDR 145.50 IDR 189.15 IDR 46
EPV 272.50 IDR 415.99 IDR 543.54 IDR 59
Dividend Discount
Gordon GGM 0.1000 IDR 0.1900 IDR 0.3200 IDR 70
DDM Multi-Stage 0.1000 IDR 0.1500 IDR 0.2100 IDR 61
Multiples
P/E Multiple 550.62 IDR 734.16 IDR 917.69 IDR 63
P/S Multiple 425.48 IDR 567.30 IDR 709.13 IDR 58
P/B Multiple 425.48 IDR 567.30 IDR 709.13 IDR 55
EV/EBIT 776.07 IDR 1,215 IDR 1,654 IDR 53
EV/EBITDA 1,161 IDR 1,728 IDR 2,295 IDR 54
EV/Revenue 399.14 IDR 801.88 IDR 1,205 IDR 43
Asset-Based
NCAV (Graham) 246.74 IDR 330.63 IDR 493.48 IDR 50
Growth DCF
Growth DCF 365.45 IDR 770.85 IDR 1,359 IDR 80
Rev-Margin DCF 341.90 IDR 835.57 IDR 1,371 IDR 74
Economic Profit
Residual Income 401.20 IDR 420.89 IDR 454.84 IDR 76
ROIC Compounder 272.50 IDR 415.99 IDR 585.17 IDR 72
Growth Earnings
Growth-Adj P/E 421.66 IDR 602.37 IDR 783.08 IDR 68

Widest divergence: DCF Models (774.12 IDR) versus Dividend Discount (0.1500 IDR). Highest evidence: Growth DCF (80).

Notify me when PEHA reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 961B IDR
Revenue growth (YoY) +10.2%
Net margin 3.7%
Return on equity 8.4%
Free cash flow 65.0B IDR FY2025
P/E ratio 6.1
More key figures
Operating margin 6.0%
EPS (TTM) 42.01 IDR
Dividend yield 1.9%
EPS growth (YoY) +92.9%
Net debt 586B IDR FY2025

Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 62 · Market factors (momentum, volatility) 30

Profitability 40
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 68
Earnings quality: real cash, not paper profit
Fin. Strength 18
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 66
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 18
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments.

Full company description

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides ethical generic and branded products; and medical devices, as well as toll manufacturing. It also exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PT Phapros Tbk, reported revenue of 941B IDR in FY2025 versus 1.1T IDR in FY2021, a compound −2.7%/yr. Reported net income was 28.0B IDR in FY2025, compounding +26.1%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
941B IDR
Latest YoY
+26.3%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−7.0%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.8%
Avg. growth/yr (14Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.1%
Revenue −2.7%/yr
FY21 1.1T IDR
FY22 1.2T IDR
FY23 1.0T IDR
FY24 745B IDR
FY25 941B IDR
Net income +26.1%/yr
FY21 11.1B IDR
FY22 28.1B IDR
FY23 6.0B IDR
FY24 −285B IDR
FY25 28.0B IDR
Character of growth · EPS growth decomposed (2014-2025) −13.9 % p.a.
Revenue per share +3.9 pp

of which total revenue +3.9 pp · buybacks/dilution +0.0 pp

EBIT margin −6.0 pp
Tax rate −1.6 pp
Residual (interest, one-offs) −10.2 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch PEHA: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Phapros Tbk, · Fair Value
734.16 IDR +176%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PT Phapros Tbk, Fair Value". https://www.fairvalue-calculator.com/stock/PEHA

Peer Group

Drug Manufacturers - Specialty & Generic · 621 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +176% · Top 25%
Return on equity (TTM) 8% · Above median
Return on assets 6% · Above median
Net margin (TTM) 4% · Below median
Operating margin (TTM) 6% · Below median
Revenue growth 10% · Above median
Dividend yield (TTM) 1.9% · Above median
Debt / equity 1.39× · Higher than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 6.1× · Cheaper than 75% of peers
P/B 0.52× · Cheaper than 75% of peers
P/S (TTM) 0.22× · Cheaper than 75% of peers
P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 3.9× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 7
FUTURE 51 · sector 21
PAST 33 · sector 24
HEALTH 31 · sector 97
DIVIDEND 39 · sector 34

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.19 ¥25.94 -51%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,933 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹7,316 ₹1,943 -73%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,763 ₹1,329 -72%
PharmaEssentia Corporation 6446 1,285 TWD 221.01 TWD -83%
Cipla Limited CIPLA ₹1,439 ₹1,001 -30%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,151 ₹703.32 -39%
Lupin Limited LUPIN ₹2,443 ₹2,477 +1%
Mankind Pharma Limited MANKIND ₹2,484 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,211 ₹874.79 -28%

Compare PT Phapros Tbk, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is PT Phapros Tbk, (PEHA) overvalued or undervalued?
As of Jul 19, 2026, our model estimates a fair value of 734.16 IDR versus a price of 266.00 IDR, about +176% (undervalued).
What is the fair value of PEHA?
Our model-based fair value for PT Phapros Tbk, is 734.16 IDR (as of Jul 19, 2026), built from audited fundamentals. The current price is 266.00 IDR.
What is the quality score of PEHA?
PT Phapros Tbk, has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PT Phapros Tbk, (PEHA)?
PT Phapros Tbk, reported trailing-twelve-month revenue of about 961B IDR (latest available figure, as of Jul 19, 2026).
What is the net profit margin of PEHA?
The net profit margin of PT Phapros Tbk, is about 3.7%, meaning it keeps roughly 3.7% of revenue as net income. Based on the latest reported figures.
Does PT Phapros Tbk, pay a dividend?
PT Phapros Tbk, currently shows a dividend yield of about 1.94% relative to its recent price (as of Jul 19, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PT Phapros Tbk, and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.